Stimwave Announces Completion of the SURF Randomized Clinical Trial of First Minimally Invasive, Miniature Wireless SCS System

Stimwave Technologies, the leading innovator of wireless medical device bioelectronic technology, today announced pending publication and completion of long-term clinical data from the SURF study.

The SURF RCT study, a prospective, randomized, multi-center clinical trial was the first ever pivotal study conducted utilizing a wirelessly powered Spinal Cord Stimulator (SCS) system comparing a variety of waveform options without a separate trialing device. Without limitations on power delivery classically associated with implantable batteries and combined with the flexibility in programming utilizing Stimwave’s proprietary multi-waveform automated WaveCrestTM iOS programming platform, the study participants were able to leverage the most state of art capabilities and options available in the industry to optimize their pain relief outcomes and dial in the appropriate waveform and frequency customized to their unique pain relief needs. Notable, in the two-arm study, high and low frequency, back and leg pain responders were over 92% and 86% respectively.